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Biodegradable metals (BMs) are metals and alloys expected to corrode gradually in vivo, with an appropriate host response elicited by
released corrosion products, then dissolve completely upon fulﬁlling the mission to assist with tissue healing with no implant residues. In
the present review article, three classes of BMs have been systematically reviewed, including Mg-based, Fe-based and Zn-based BMs.
Among the three BM systems, Mg-based BMs, which now have several systems reported the successful of clinical trial results, are
considered the vanguards and main force. Fe-based BMs, with pure iron and Fe–Mn based alloys as the most promising, are still on the
animal test stage. Zn-based BMs, supposed to have the degradation rate between the fast Mg-based BMs and the slow Fe-based BMs, are a
rising star with only several reports and need much further research. The future research and development direction for the BMs are
proposed, based on the clinical requirements on controllable degradation rate, prolonged mechanical stability and excellent biocompat-
ibility, by optimization of alloy composition design, regulation on microstructure and mechanical properties, and following surface
modiﬁcation.
& 2014 Chinese Materials Research Society. Production and hosting by Elsevier B.V. All rights reserved.
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With the development of society and the improvement of
living standards, the expectation for a better quality of life
has been increasing. Researchers have to develop new
materials and technologies in order to provide implants with
higher clinical performance. In practical clinic applications,
some speciﬁc clinical problems (such as bone fracture and
vessel blockages) need only temporary support for tissue
healing process. This temporary support can only be
provided by an implant made of degradable biomaterials
which allow the implant to progressively degrade after
fulﬁlling its function. The concept of biodegradation has
been known in medical applications for a long time, such as/10.1016/j.pnsc.2014.08.014
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implants that degrade, especially those made of metals and
alloys, can be considered as a novel concept which actually
breaks the established paradigm of “metallic biomaterials
must be corrosion-resistant”[1].
The deﬁnition of biodegradable metals (BMs) had been
given as follows: BMs are metals expected to corrode
gradually in vivo, with an appropriate host response elicited
by released corrosion products, then dissolve completely
upon fulﬁlling the mission to assist with tissue healing with
no implant residues. Therefore, the major component of BMs
should be essential metallic elements that can be metabolized
by the human body, and demonstrate appropriate degradation
rates and modes in the human body [2].Elsevier B.V. All rights reserved.
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systems: Mg-based BMs [3–9] (pure Mg, Mg–Ca alloys, Mg–Zn
alloys, Mg–Sr alloys, Mg–RE alloys, Mg-based bulk metallic
glasses (BMGs), etc.), Fe-based BMs [10–13] (pure Fe, Fe–Mn
alloys, Fe–W alloys etc.), Zn-based BMs [14–17] (pure Zn, Zn–
Mg alloys and Zn-based bulk metallic glasses) and other BMs
(Ca-based [18–21] and Sr-based BMGs [22–24], etc.). Fig. 1
shows the research status of the three main body BM systems:
Mg-based BMs [4,7,9,25–42], Fe-based BMs [12,13,43–49], and
Zn-based BMs [15–17,50–52]. It is quite clear that among these
BMs, Mg-based BMs [3–9] are the research's vanguard and main
force with hundreds of publications on the in vitro cytoxicity,
animal testing and clinical trails, Fe-based BMs [10–13] are
reported in tens of publications on alloy design and several
animal testing as potential vascular stent, Zn-based BMs [14–17]
are referred with less than ten publications but seems to be a
rising star in the family of biodegradable metals.2. Mg-based BMs
Mg based BMs are attractive for biodegradable implants
because of their good mechanical properties and biocompat-
ibilities. Promising Mg alloying systems including Mg–Ca,
Mg–Sr, Mg–Zn, Mg–Si, Mg–Sn, Mg–Mn, Mg–RE and Mg–
Ag have been developed [3–9]. The microstructures, mechan-
ical properties, degradation behavior, ion release, in vitro and
in vivo animal biocompatibility studies and clinical trials
have been widely explored in order to evaluate their
feasibility for biomedical purposes.Fig. 1. Research status of the three BM systems: Mg-based BMs [4,7,9,25–422.1. Mechanical properties
Fig. 2 shows the tensile properties of magnesium alloys,
including pure Mg [30], Mg–Zn–Mn [53], Mg–Ca [4], Mg–
Sr [7], Mg–Si [30], Mg–Zr [30], AZ91D [54], AZ31 [54],
LAE442 [54], WE43 [54].
It is quite clear that magnesium alloys have a large range of
ultimate tensile strength (UTS) and elongation to failure (EL),
from 86.8 to 300 MPa and from 3% to 30%, respectively.
Alloying and processing history have great effect on the
mechanical properties of magnesium alloys. Adding Sn, Si,
Zr and Zn can improve both the UTS and EL [30], while Ca,
Sr and Mn will deteriorate their ductility to some extent
[4,7,30]. Processing deformation (including hot rolling, hot
extruding, and ECAP) also contribute to the strength and
elongation of magnesium alloys [4,7,32].2.2. Corrosion behavior
Although the reported inspiring results indicated that Mg-
based BMs may be possible alternatives for permanent
biomaterials. However, Mg-based BMs have rapid degrada-
tion rates in body ﬂuids. The rapid degradation rate would
result in the loss of mechanical integrity in a short period
which can limit its application as an implant material. To
control the biodegradation rate of Mg-base BMs, selection on
alloying elements, microstructural adjustment and surface
modiﬁcation methods have been applied.], Fe-based BMs [12,13,43–49], and Zn-based BMs [15–17,50–52].
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[53]
[54]Addition of the alloying elements. WE43, ZW21 and WZ21
containing Zn, Y, Ca RE (rare earth metal) and Mn as
alloying elements showed ﬁne and even microstructures with
grain sizes smaller than 10 mm, which generated exceptional
plasticity of 17% and 20% at ambient temperature [55–57].
These WE43, ZW21 and WZ21 alloys also exhibited fairly
homogeneous degradation behavior in physiologically simu-
lated solutions and a higher corrosion resistance than that of
ZQ30 alloy magnesium alloys [55,56]. In vitro cell tests
indicated good cytocompatibility. Animal implantation stu-
dies of WZ21 alloy disc specimens revealed a promising
in vivo performance of the alloy [56].(2) Slowing down the biodegradation rate by surface coatings.
HA coatings were produced on AZ91D in a two-step
process, which was shown to slow down the corrosion
process in SBF [58]. PCL coatings were developed on
AZ91 samples. Polarization and immersion tests in SBF
were carried out, which showed that the polymer coating
reduced the degradation rate, which was controlled by the
degree of porosity. A two-step coating process was
introduced for WE42 alloy, and corrosion studies using
polarization and EIS methods in Hank's solution showed
increased corrosion resistance after coating [59].(3) Composited with other degradable biomaterials. Adding
ZnO into Mg-based BM matrix to form composites is
proved to improve the tensile strength, surface hardness,
and corrosion resistance [60].(4) Microstructural reﬁnement. Ultraﬁne-grained structure of
Mg-based BMs obtained by rapid solidiﬁcation (RS) [61]
or severe plastic deformation techniques (SPD), such as the
equal channel angular pressing (ECAP) [62], high pressure
torsion (HPT) [63], or cyclic extrusion and compression
(CEC) [64] are favorable for mechanical properties and
corrosion resistance. The grain size of Mg–3Ca alloy was
reﬁned to 200–500 nm by rapid solidiﬁcation (RS) and the2. Tensile properties of magnesium alloys: pure Mg [30], Mg–Zn–Mn
, Mg–Ca [4], Mg–Sr [7], Mg–Si [30], Mg–Zr [30], AZ91D [54], AZ31
, LAE442 [54], WE43 [54].grain size decreased with increasing cooling rate. In compar-
ison with the as-cast Mg–3Ca alloy, the Mg–3Ca alloy with
ultraﬁne-grained structure processed by RS exhibited drama-
tically reduced degradation rate from 21 mm/yr to 0.36–
1.43 mm/yr (the higher the RS speed, the lower the degrada-
tion rate) and exhibited more uniform corrosion morphology
on the surface [65]. The as-CECed Mg–Nd–Zn–Zr alloy
exhibited ﬁne grain size (about 1 μm) and largely improved
tensile properties (71% and 154% higher YS and elongation
than the as-extruded Mg–Nd–Zn–Zr alloy). The degradation
rate was slowed down after CEC process [66]. Similarly, the
ultraﬁne-grained Mg–Zn–Ca alloy prepared by the HPT
process demonstrated improved corrosion resistance com-
pared to its as-extruded counterpart [63].(5) Glassy structure. Compared with conventional crystalline
pure Mg and Mg alloys, Mg-based BMGs with amorphous
microstructure have been found to have higher corrosion
resistance, higher strength and lower elastic modulus due to
the single structure without defects of grain boundary. Zberg et
al. [31] and Gu et al. [9] have studied the corrosion behavior,
cellular response and tissue response of Mg–Zn–Ca BMGs
and the results demonstrated that Mg–Zn–Ca BMGs present
more uniform corrosion morphology compared with conven-
tional crystalline Mg alloys and has much lower corrosion
rates, and show higher cell viabilities than conventional
crystalline pure Mg. In addition, the in vivo study indicated
that no tissue-imprinted hydrogen gas cavities have formed in
the histological preparations of the Mg–Zn–Ca BMG samples
and no inﬂammatory reaction was observed [31]. To make the
ﬁnal medical devices such as woven stent of Mg-based BMGs,
Zberg et al. [67] produced wires with very good surface quality
via a melt-extraction setup which show extended homogeneous
plastic deformation in tensile tests. A signiﬁcantly improved
ductility of Mg-based BMGs under bending and tensile
loading through minor alloying with rare-earth element
ytterbium (Yb) was done by Yu et al. [68], and the achieved
plastic strain was about 0.5% after adding 2% and 4% Yb into
MgZnCa glasses. Additionally the in vitro biocompatibility of
Mg-based BMGs was also improved by Yb-alloying as
conﬁrmed by indirect cytotoxicity and direct cell adhesion,
extension and proliferation assays [68].2.3. Clinical trials
In 2005, Zartner et al. [26] reported that they have success-
fully rescued the life of a preterm baby from an extremely severe
clinical congenital heart disease via implanting a biodegradable
Mg stent in the left pulmonary artery of the baby. The follow-up
procedure showed the complete degradation occurred during 5
months and no in-stent obstruction or neointimal hypertrophy
could be observed [26]. WE43 stents were implanted into the
coronary arteries of 63 patients. Angiography at 4 months
showed an increased diameter stenosis of 17.0%. After serial
intravascular ultrasound examinations, only small remnants of
Fig. 3. Tensile properties of iron alloys: pure Fe [69], Fe–3C [12], Fe–3S [12],
Fe–3W [12], Fe–10Mn [10], Fe–10Mn–1Pd [10], Fe–30Mn (forged) [70], Fe–
30Mn (cast)[13], Fe–30Mn–1C [70], Fe–30Mn–6Si [13].
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Neointimal growth and negative remodeling were the main
operating mechanisms of restenosis [29]. Drug-eluting Mg-
based scaffold (DREAMS) was implanted into 46 symptomatic
patients with de-novo coronary lesions and clinical follow-up
was scheduled at 1, 6, 12, 24, and 36 months. Two of 46 (4%)
patients had target lesion failure at 6 months (both clinically
driven target lesion revascularizations), which rose to three of 43
(7%) at 12 months (one periprocedural target vessel myocardial
infarction occurred during angiography at the 12 month follow-
up visit). No cardiac death or scaffold thrombosis was noted
[35].
3. Fe-based BMs
3.1. Mechanical properties
Fig. 3 summarized the mechanical properties of Fe-based
BMs including pure Fe [69], Fe–3C [12], Fe–3S [12], Fe–3W
[12], Fe–10Mn [10], Fe–10Mn–1Pd [10], Fe–30Mn (forged)
[70], Fe–30Mn (cast)[13], Fe–30Mn–1C [70], Fe–30Mn–6Si
[13].
From Fig. 3 we can see that Fe-based BMs have high
strength (up to 1450 MPa) and high ductility (up to 80%
elongation) thus make them favored candidates for biode-
gradable stents. The high strength can be helpful in making
stents with thinner struts. The high ductility can be helpful
during the implantation of stent when the stent is plastically
deformed.
3.2. Biocompatibility evaluations
Up to now, there is no clinical report about Fe-based stents.
Several animal tests have been reported and the main results
are listed below.Peuster et al. ﬁrstly implanted pure Fe into descending
aorta of New Zealand white rabbits [43] and minipigs [44] as
bio-
degradable stent. The results showed no signiﬁcant evidence
of inﬂammatory response or neointimal proliferation, and
organ examination did not reveal any systemic toxicity. There
was also a maintained stent patency and no adverse events
during a 6–18 month follow-up. Besides, the stents main-
tained their mechanical properties during the implantation
without any failure. However, their results demonstrated that
faster degradation rate is desirable for iron and further studies
have to focus on the modiﬁcation of the composition and
design of the stent to expedite the degradation process
[43,44]. The suggested mechanisms were either using iron-
based alloys with a more pronounced corrosion rate or
increasing the surface of the stent along with reduction of
the strut thickness and modiﬁcation of the stent design [71].
3.3. Acceleration on biodegradation rate
Based on these above in vivo test results, following
investigations have been performed in order to accelerate
the degradation rate of Fe-based BMs while still maintaining
their mechanical properties. On the one hand, Mn, Pd, W, Sn,
B, C, S, Si, etc. were introduced into Fe as alloying elements
[12,13]. The corrosion rate of Fe30Mn6Si alloy was higher
than that of Fe30Mn alloy. Fe30Mn6Si alloy showed to
inhibit the metabolic activity of human endothelial cells
(ECV304) and rodent VSMC to a higher extend compared
to pure iron [13]. The alloying elements, including Mn, Co,
W, B, C, and S were found to improve the yield and ultimate
strength of iron, whereas the alloying element Sn led to a
severe reduction in the mechanical properties [12].
Microstructure adjustment is another factor that has been
employed to modify the corrosion rate of Fe BMs. Generally,
the corrosion of electroformed iron is higher. The smaller
grains of electroformed iron provide higher grain boundary
area and are more susceptible to the corrosive attack. The
high density of microstructural defects in electroformed iron
is another reason for the higher corrosion rate [72]. The
corrosion mechanism of electroformed iron appeared to be
uniform as no localized attack was observed after the
degradation testing. Besides, electroformed iron has no
inhibition to cell metabolic activity of primary rat SMCs
compared to 316L SS [72].
4. Zn-based BMs
4.1. Unique advantages of Zn-based BMs
Zinc is an essential element for human beings, and it is the
second most abundant transition metal element in human
body [73]. Zinc serves as a cofactor in all six classes of
enzymes [74] as well as several classes of regulatory proteins
Table 1
Comparison of the corrosion rates of the Mg-, Fe- and Zn-based BMs.
Alloy system State In vitro (mm/year) In vivo (mm/year) References
Electrochemical test Immersion test
Mg BMs Mg 0.20 0.1070.07 [76]
Mg–6Zn Extruded 0.16 0.0770.02 2.3270.11 [76]
Mg–1Ca Cast 12.56 1.27 [4]
LAE442 Cast 6.9 5.535 0.4670.11 [28,77]
Mg–10Gd Cast 1.2570.2 [8]
Mg–8Y Cast 2.1770.23 [78]
Mg–0.8Ca Extruded 0.3970.1 [79]
Mg–2Sr Rolled 0.8770.08 0.3770.05 1.0170.07 [7]
Fe BMs Fe Cast 0.105 0.012 [12]
Fe–2W SPS 0.075 0.026 [80]
Fe–0.5CNT SPS 0.099 0.048 [80]
Fe–Mn Cast 0.105 0.0018 [12]
Fe–W Cast 0.151 0.016 [12]
Zn BMs Zn Cast 0.08 0.02 [16]
Zn–1Mg Cast 0.09 [16]
Fig. 4. Future research directions of Zn-based BMs.
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Mg-based BMs.
According to the standard electrode potential, i.e. Mg
(2.37V)oZn (0.763V)oFe(0.440V) (vs. SHE),
which means that Zn has a corrosion rate faster than Fe,
but slower than Mg. Table 1 summarizes the corrosion rates
of the Mg-, Fe-, and Zn-based BMs. Considering Mg-based
BMs need decreased degradation rate while the Fe-based
BMs need enhanced degradation rate, Zn-based BMs are
believed to be the next rising stars in the BM family.4.2. Research status of Zn-based BMs
At present, there is only 1 scientiﬁc paper reported the
in vivo results on Zn-based BMs. Pure zinc wires were placedinto the arteries of rats and they degraded at a rate just below
0.2 mm per year—the “magic” value for bioabsorbable stents
—for the ﬁrst three months. After that, the corrosion
accelerated, so the implant would not remain in the artery
for too long. Moreover, the rats' arteries appeared healthy
when the wires were removed, with tissue ﬁrmly grasping the
implant [15].4.3. Future research directions of Zn-based BMs
One drawback of pure Zn as potential biodegradable metal
lies in that pure Zn has quite low strength and plasticity
(UTSo20 MPa and ELo30% for the as cast pure Zn [16]).
In order to modify the mechanical properties of pure Zn,
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would be the appropriate ways, as illustrated in Fig. 4.
4.3.1. Choosing appropriate alloying elements and form new
Zn-based BMs
Mg was chosen as the alloying element and formed Zn–Mg
binary alloys by casting method. The as cast Zn–Mg binary
alloys were found to have greatly-enhanced microhardness,
tensile strength, elongation compared with pure Zn
[16,17,81]. Besides the reported Zn–Mg BMs, the essential
nutrient Ca, Sr, Sn, Fe and other alloying elements RE, Li,
Mn, Si which commonly applied as alloying elements in
biomedical Mg-based and Fe-based BMs can be considered
as the potential alloying elements when developing new Zn-
based BMs.
4.3.2. Hot/cold working
Mechanical deformation is another effective mean to
improve the mechanical and corrosion properties of BMs
[2,4,61]. Rolling (hot/cold), extrusion, equal-channel angular
pressing (ECAP), high pressure torsion (HPT), drawing,
forging are the most commonly-used process methods for
BMs' properties enhancement. It has been reported that these
severe plastic deformation methods have dramatically
improved the mechanical strength [82–85], elongation
[82,83,85], vickers' hardness [86–88], corrosion behavior
[86,89–91], biocompatibility [92] of BMs. Clearly these are
adoptable and promising techniques for Zn-based BMs in the
future.
4.3.3. Zn-based nanocrystalline and BMGs
It is well known that the mechanical properties, corrosion
behaviors and biocompatibility of metallic alloys are strongly
inﬂuenced by alloying elements as well as by the micro-
structure. Materials with amorphous, nano- or quasicrystalline
structure [93] that exhibit very promising physical, mechan-
ical and chemical properties, e.g. high corrosion resistance.
In general, nanocrystallinity is assumed to improve the
mechanical behavior as well as the corrosion resistance[94] of
an alloy as compared to its conventional counterpart. A
reason for such a behavior might be a higher diffusivity due
to the high ratio of surface to volume due to the presence of
large number of grain boundaries, thus improving the
formation of a protective layer. Furthermore, the higher
homogeneity allows a better distribution of contamination
because of the increased area of grain boundaries, thus
reducing local segregation[95].
It is well known that glassy alloys offer superior resistance
to corrosion and vastly improved mechanical properties over
their conventional counterparts. Amorphous alloys have often
a corrosion resistance one to two orders of magnitude higher
than polycrystalline alloys with the same alloy composition
[95–97]. Zn-based BMGs were ﬁrstly developed by Jiao and
co-workers in 2010 [14], and they further studied theirmagnetic susceptibility, mechanical properties, corrosion
behavior and cytocompatibility [50] aiming to develop this
new kind of Zn-based BMGs as new kind of bone repair and
ﬁxation materials. It was found that Zn-based BMG with
composition of Zn38Ca32Mg12Yb18 shows much higher
strength (above 600 MPa) than conventional Mg (about
200 MPa) crystalline materials, much smaller magnetic sus-
ceptibility (22.3 106) than that of commonly used biome-
dical alloys, slower degradation rate than pure Mg and hardly
any hydrogen is generated during the immersion time. Its
compression fracture strength did not show obvious decline
after immersed in Hank's solution for 30 days. Cytotoxicity
test revealed that this Zn-based BMG shows good cytocom-
patibility to MG63 osteoblast cells.4.3.4. Zn-based BM composites and porous BMs
Composites with enhancement phases, either metal (Fe,
Mg, Ca, Ti, Zr etc.) or non-metal (HA, ZnO, Al2O3 etc.) can
further improve the mechanical, corrosion properties and the
biocompatibility of Zn-based BMs. The porous scaffold
provides the necessary support for cells to proliferate and
maintain their differentiated function, and its architecture
deﬁnes the ultimate shape of the new bone.5. Concluding remarks
The family of biodegradable alloys now mainly consists of
three alloy systems, including Mg-based BMs as the
research's main body and at the stage of clinical trial stage,
the Fe-based BMs at the animal testing stage and the Zn-
based BMs at initial development stage. Investigations are
still ongoing in this ﬁeld in order to get the optimized BMs
that meet the clinical requirements, including controllable
degradation rate, prolonged mechanical stability and excellent
biocompatibility. These targets can be achieved through
optimization of alloy composition design, microstructure
and mechanical property alternation and surface modiﬁcation.
The following aspects are the main research in the BM area.5.1. New alloy systems
Along with the optimization on the present Mg-based,
Fe-based and Zn-based alloy systems, with the essential
elements of the human body, C, H, O, N, Ca, K, Na, P,
Mg, S, Si, Fe, Zn, Se, Cu, Mo, Sn, Co, Mn and Sr, as alloying
elements. There will be a consideration on the adding content
for each element, based on the material science (for instance,
according to the phase diagram how much should be added to
obtain the best microstructure and mechanical property) and
the biomedicine (for example, the critical value for a certain
element by daily food uptake).
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Amorphous structure can bring about unique properties for
materials, thus developing novel BMs with amorphous
structure will make new breakthroughs. A case in point is
that due to the excessively active chemical reactivity of Ca
and Sr, the design and development of conventional crystal-
line pure
Ca- and Sr- based BMs for biomedical application is infeasible.
However, with amorphous structure, the Ca-based [21,50,98–
100], Sr-based [22,101] BMs have been developed which
dramatically slowed down the corrosion rate of their crystalline
counterparts.
5.3. BM composited with macromolecules and/or ceramics
Macromolecules and/or ceramics have been used in clinics
for many years and possess quite different properties com-
pared with metals and alloys. BM composites with macro-
molecules and/or ceramics can combine the strengths of
alloys and macromolecules and/or ceramics together.
5.4. Advanced manufacturing technology
By using 3-D printing technology, the BMs can be directly
processed into scaffolds, implants, organs and other tissues
which needed in clinical applications. In order to fabricate
synthetic bone scaffolds, three-dimensional (3-D) porous
structures have been pursued to allow for bony ingrowth,
inﬁltration of cells and ﬂuids, and to mimic the natural
cellular structure of bone. It has been possible to create a
controllable porous, interconnected architecture via 3-D
printing technology. Open-cell porous Mg with controllable
macroscopic architectures by 3-D printing [102]. It is found
that the method is capable of replicating highly accurate
porous structures (5–12% error) with macroscopic features
as ﬁne as 0.8 mm. By using inkjet 3-D printing, a technique
which generates complex, customizable parts from powders
mechanically milled Fe–30Mn (wt%) powder was directly
processed into scaffolds [103]. Study suggests that the printed
scaffolds demonstrated tensile mechanical property values
very similar to those of natural bone and it presented an
estimated corrosion rate that is higher than that of pure iron,
while depositing corrosion products containing bone mineral
components Ca and P, indicating its promise for bone
replacement. Based on these preliminary studies, we believe
that 3-D printing is a promising technology for biomedical
applications, and bring new opportunity for the biodegradable
metals to be fabricated using this unique method.
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